Phenmetrazine

Phenmetrazine

Clinical data
Routes of administration	Oral, Intravenous, Vaporized, Insufflated, Suppository
Legal status
Legal status	CA: Schedule IV UK: Class B US: Schedule II
Pharmacokinetic data
Elimination half-life	8 hours
Excretion	Renal
Identifiers
IUPAC name 3-methyl-2-phenylmorpholine
CAS Number	134-49-6
PubChem CID	4762
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C11H15NO
Molar mass	177.2456

Phenmetrazine is a stimulant of the central nervous system. It was previously sold under the trade name Preludin as an anorectic. Preludin has since been removed from the market. It was initially replaced by the weaker analogue Phendimetrazine (Bontril), but this is now only rarely prescribed, due to problems with abuse.

Other names that have been used for Phenmetrazine include: Defenmetrazin, Fenmetrazin, Oxazimedrine, Phenmetraline.

History

It was first patented in Germany in 1952 by Boehringer-Ingelheim. It was the result of a search by Thomae and Wick for an anorectic substance without the side-effects of amphetamine . Phenmetrazine was introduced into clinical use in 1954 in Europe .

Medical use

In clinical use phenmetrazine produces less nervousness, hyperexcitability, euphoria and insomnia than the amphetamines. It doesn't tend to increase the pulse either. Due to the relative lack of side-effects, one study found it well tolerated in children. In a study of the effectiveness on weight loss between phenmetrazine and dextroamphetamine, phenmetrazine was found to be slightly more efficient.

Even though the manufacturers claimed it had "exceptional safety and strikingly low incidence of side effects", within some years there were some reports of psychotic reactions of the amphetamine type.

Pharmacology

Phenmetrazine produces its action by causing release of noradrenaline and dopamine in the central nervous system.

After an oral dose, about 70% of the drug is excreted from the body within 24 hours. About 19% of that is excreted as the unmetabolised drug and the rest as various metabolites

In trials in rats it has been found that after subcutaneous administration, both the optical isomers of phenmetrazine is equally effective in reducing food intake, but in oral administration the levo isomer is more effective. In terms of central stimulation however, the dextro isomer is about 4 times as effective in both methods of administration.

Abuse

It is by some considered to have a greater potential for addiction than the amphetamines, and has been abused in many countries, for example Sweden. When stimulant abuse first became prevalent in Sweden in the 1950s, phenmetrazine was preferred to amphetamine and methamphetamine by addicts, as it was considered the superior drug. In the autobiographical novel "Rush" by Kim Wozencraft, intravenous phenmetrazine is described as the most euphoric and pro-sexual of the stimulants the author used.

Phenmetrazine was classified as a narcotic in Sweden in 1959, and was taken completely off the market in 1965. At first the illegal demand was satisfied by smuggling from Germany and later Spain and Italy. At first Preludin tablets were smuggled, but soon the smugglers started bringing in raw phenmetrazine powder. Eventually Amphetamine became the dominant stimulant of abuse because of its easier availability.

The drug was taken by The Beatles early in their career. Paul McCartney was one known user. McCartney's introduction to drugs started in Hamburg, Germany. The Beatles had to play for hours, and they were often given "Prellies" (Preludin) by German customers or by Astrid Kirchherr (whose mother bought them). McCartney would usually take one, but John Lennon would often take four or five.

References

Template:WikiDoc Sources